B-cell-depletion reverses dysbiosis of the microbiome in multiple sclerosis patients

Troci, Alba; Zimmermann, Olga; Esser, Daniela; Krampitz, Paula; May, Sandra; Franke, André; Berg, Daniela; Leypoldt, Frank; Stürner, Klarissa Hanja; Bang, Corinna

doi:10.1038/s41598-022-07336-8

Cited by 17 publications

(11 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…calcoaceticus both increased (induced proinflammatory responses), but Parabacteroides distasonis was reduced (stimulated anti-inflammatory IL-10-expressing) [99]. In addition, the abundance of Bacteroidetes, Lachnospiraceae, Rikenellaceae, Eisenbergiella, Escherichia-Shigella, F. prausnitzii, and Flavobacterium increased in patients with MS, whereas Firmicutes, Ruminococcaceae, Bacteroides, Bifidobacterium, Clostridium, L. salivarius, L. iners, L. ruminis, Megamonas, Odoribacter, Parabacteroides, and Prevotella decreased [99,[114][115][116][117][118][119][120][121][122][123][124][125][126][127][128] (Fig. 4).…”

Section: Multiple Sclerosismentioning

confidence: 99%

The role of gut microbiota in T cell immunity and immune mediated disorders

Shim¹,

Ryu²,

Jo³

et al. 2023

Int. J. Biol. Sci.

View full text Add to dashboard Cite

Gut microbiota was only considered as a commensal organism that aids in digestion, but recent studies revealed that the microbiome play a critical role in both physiological and pathological immune system. The gut microbiome composition is altered by environmental factors such as diet and hygiene, and the alteration affects immune cells, especially T cells. Advanced genomic techniques in microbiome research defined that specific microbes regulate T cell responses and the pathogenesis of immune-mediated disorders. Here, we review features of specific microbes-T cell crosstalk and relationship between the microbes and immunopathogenesis of diseases including in cancers, autoimmune disorders and allergic inflammations. We also discuss the limitations of current experimental animal models, cutting-edge developments and current challenges to overcome in the field, and the possibility of considering gut microbiome in the development of new drug.

show abstract

Section: Multiple Sclerosismentioning

confidence: 99%

The role of gut microbiota in T cell immunity and immune mediated disorders

Shim¹,

Ryu²,

Jo³

et al. 2023

Int. J. Biol. Sci.

View full text Add to dashboard Cite

show abstract

“…7 A). To validate this model, we used an independent German cohort 23 . We inferred the microbiota-derived metabolites of the 38 HVs and the 12 treatment-free RRMS patients.…”

Section: Resultsmentioning

confidence: 99%

“…Dysbiosis of the oral microbiome in MS patients has been previously described. In a longitudinal study of oral swabs 23 , there were significant increases in the relative abundance of Campylobacter, Haemophilus and Neisseria . In a second study 24 , DNA sequencing of cultured bacterial isolates from oral swabs by PCR revealed that Staphylococcus, Actinomyces, Fusobacterium, Bacteroides, Porphyromonas, Prevotella, Veillonella and Propionibacterium were significantly more abundant in the MS group than in the control group, while Lactobacillus and Peptostreptococcus were more prevalent in the HV group.…”

Section: Discussionmentioning

confidence: 97%

“…t-SNE dimensional reductions were performed on both taxonomy (at the genus level) and metabolic fluxes to observe the discrimination power of each of the two levels of resolution in the faecal and oral samples. Finally, we created a discrimination model based on logistic regression analysis of the microbiome-derived metabolites and tested it on an oral microbiome analysis of an independent set of individuals, performed at Kiel University (Kiel, Germany) using 16S rRNA 23 . Briefly, taxonomic tables were gathered for 38 HV and 12 MS patients free of any DMT.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Investigating the metabolite signature of an altered oral microbiota as a discriminant factor for multiple sclerosis: a pilot study

Boussamet,

Montassier,

Mathé

et al. 2024

Sci Rep

Self Cite

View full text Add to dashboard Cite

In multiple sclerosis (MS), alterations of the gut microbiota lead to inflammation. However, the role of other microbiomes in the body in MS has not been fully elucidated. In a pilot case-controlled study, we carried out simultaneous characterization of faecal and oral microbiota and conducted an in-depth analysis of bacterial alterations associated with MS. Using 16S rRNA sequencing and metabolic inference tools, we compared the oral/faecal microbiota and bacterial metabolism pathways in French MS patients (n = 14) and healthy volunteers (HV, n = 21). A classification model based on metabolite flux balance was established and validated in an independent German cohort (MS n = 12, HV n = 38). Our analysis revealed decreases in diversity indices and oral/faecal compartmentalization, the depletion of commensal bacteria (Aggregatibacter and Streptococcus in saliva and Coprobacter and Roseburia in faeces) and enrichment of inflammation-associated bacteria in MS patients (Leptotrichia and Fusobacterium in saliva and Enterobacteriaceae and Actinomyces in faeces). Several microbial pathways were also altered (the polyamine pathway and remodelling of bacterial surface antigens and energetic metabolism) while flux balance analysis revealed associated alterations in metabolite production in MS (nitrogen and nucleoside). Based on this analysis, we identified a specific oral metabolite signature in MS patients, that could discriminate MS patients from HV and rheumatoid arthritis patients. This signature allowed us to create and validate a discrimination model on an independent cohort, which reached a specificity of 92%. Overall, the oral and faecal microbiomes were altered in MS patients. This pilot study highlights the need to study the oral microbiota and oral health implications in patients with autoimmune diseases on a larger scale and suggests that knowledge of the salivary microbiome could help guide the identification of new pathogenic mechanisms associated with the microbiota in MS patients.

show abstract

“…Figure 3 illustrates the potential role of gut dysbiosis in MS, although the directionality of this interaction is not clear. Gut microbes are definitely altered in MS patients, and this alteration is associated with the varied severity of the disease ( 125 – 128 ). The microbiome signature in MS patients is characterized by the lower abundance of F. prausnitzii , Prevotella , and Bacteroides , and a higher abundance of Akkermansia muciniphila ( 126 , 128 ).…”

Section: Microbial Dysbiosis Drives Systemic Autoimmune Diseasesmentioning

confidence: 99%

Microbial dysbiosis in the gut drives systemic autoimmune diseases

Mousa

Chehadeh²,

Husband³

2022

Front. Immunol.

View full text Add to dashboard Cite

Trillions of microbes survive and thrive inside the human body. These tiny creatures are crucial to the development and maturation of our immune system and to maintain gut immune homeostasis. Microbial dysbiosis is the main driver of local inflammatory and autoimmune diseases such as colitis and inflammatory bowel diseases. Dysbiosis in the gut can also drive systemic autoimmune diseases such as type 1 diabetes, rheumatic arthritis, and multiple sclerosis. Gut microbes directly interact with the immune system by multiple mechanisms including modulation of the host microRNAs affecting gene expression at the post-transcriptional level or production of microbial metabolites that interact with cellular receptors such as TLRs and GPCRs. This interaction modulates crucial immune functions such as differentiation of lymphocytes, production of interleukins, or controlling the leakage of inflammatory molecules from the gut to the systemic circulation. In this review, we compile and analyze data to gain insights into the underpinning mechanisms mediating systemic autoimmune diseases. Understanding how gut microbes can trigger or protect from systemic autoimmune diseases is crucial to (1) tackle these diseases through diet or lifestyle modification, (2) develop new microbiome-based therapeutics such as prebiotics or probiotics, (3) identify diagnostic biomarkers to predict disease risk, and (4) observe and intervene with microbial population change with the flare-up of autoimmune responses. Considering the microbiome signature as a crucial player in systemic autoimmune diseases might hold a promise to turn these untreatable diseases into manageable or preventable ones.

show abstract

B-cell-depletion reverses dysbiosis of the microbiome in multiple sclerosis patients

Cited by 17 publications

References 25 publications

The role of gut microbiota in T cell immunity and immune mediated disorders

The role of gut microbiota in T cell immunity and immune mediated disorders

Investigating the metabolite signature of an altered oral microbiota as a discriminant factor for multiple sclerosis: a pilot study

Microbial dysbiosis in the gut drives systemic autoimmune diseases

Contact Info

Product

Resources

About